RaQualia Pharma Inc.
4579.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥775 | ¥571 | ¥965 | ¥738 |
| % Growth | 35.8% | -40.9% | 30.8% | – |
| Cost of Goods Sold | ¥227 | ¥235 | ¥293 | ¥229 |
| Gross Profit | ¥549 | ¥335 | ¥673 | ¥509 |
| % Margin | 70.8% | 58.8% | 69.7% | 69% |
| R&D Expenses | ¥455 | ¥397 | ¥385 | ¥449 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥84 |
| SG&A Expenses | ¥248 | ¥221 | ¥194 | ¥247 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥703 | ¥619 | ¥579 | ¥695 |
| Operating Income | -¥155 | -¥283 | ¥93 | -¥186 |
| % Margin | -19.9% | -49.7% | 9.6% | -25.2% |
| Other Income/Exp. Net | ¥19 | -¥37 | -¥64 | ¥56 |
| Pre-Tax Income | -¥135 | -¥321 | ¥29 | -¥130 |
| Tax Expense | ¥79 | ¥29 | ¥34 | ¥25 |
| Net Income | -¥214 | -¥350 | -¥5 | -¥155 |
| % Margin | -27.6% | -61.3% | -0.5% | -21% |
| EPS | -8.76 | -15.25 | -0.24 | -7.16 |
| % Growth | 42.6% | -6,254.2% | 96.6% | – |
| EPS Diluted | -8.76 | -15.25 | -0.24 | -7.16 |
| Weighted Avg Shares Out | 24 | 23 | 22 | 22 |
| Weighted Avg Shares Out Dil | 24 | 23 | 22 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥6 | ¥5 | ¥4 | ¥3 |
| Interest Expense | ¥15 | ¥16 | ¥15 | ¥14 |
| Depreciation & Amortization | ¥121 | ¥119 | ¥118 | ¥121 |
| EBITDA | ¥1 | -¥185 | ¥162 | ¥5 |
| % Margin | 0.1% | -32.4% | 16.8% | 0.7% |